509 related articles for article (PubMed ID: 16740733)
1. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
2. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
3. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
Zhang T; Barber A; Sentman CL
Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
[TBL] [Abstract][Full Text] [Related]
4. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
5. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
7. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
8. Exosomes and the MICA-NKG2D system in cancer.
Clayton A; Tabi Z
Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
[TBL] [Abstract][Full Text] [Related]
9. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
[TBL] [Abstract][Full Text] [Related]
10. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
12. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
[TBL] [Abstract][Full Text] [Related]
14. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
15. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
16. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
17. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
19. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
20. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]